NVOPartnership•prnewswire•
Replicate Bioscience Announces Partnership with Novo Nordisk to Unlock Self-Replicating RNA Therapies for Obesity and Diabetes
Sentiment:Positive (70)
Summary
Partnership leverages Replicate's proprietary srRNA technology to create novel, scalable therapies for obesity, type 2 diabetes and other cardiometabolic diseases Replicate will receive research funding and could potentially receive up to approximately US$550 million, in addition to...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 28, 2025 by prnewswire